Global Kidney Cancer Drugs Market Insights, Forecast to 2025

1 Study Coverage

• 1.1 Kidney Cancer Drugs Product Introduction
• 1.2 Market Segments
• 1.3 Key Kidney Cancer Drugs Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Kidney Cancer Drugs Market Size Growth Rate by Type
  • 1.4.2 Angiogenesis Inhibitors
  • 1.4.3 mTOR Inhibitors
  • 1.4.4 Monoclonal Antibodies
  • 1.4.5 Cytokine Immunotherapy (IL-2)
• 1.5 Market by Application
  • 1.5.1 Global Kidney Cancer Drugs Market Size Growth Rate by Application
  • 1.5.2 Renal cell carcinoma (RCC)
  • 1.5.3 Transitional cell carcinoma (TCC)
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Kidney Cancer Drugs Market Size, Estimates and Forecasts
  • 2.1.1 Global Kidney Cancer Drugs Revenue 2015-2026
  • 2.1.2 Global Kidney Cancer Drugs Sales 2015-2026
• 2.2 Global Kidney Cancer Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Kidney Cancer Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Kidney Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Kidney Cancer Drugs Competitor Landscape by Players

• 3.1 Kidney Cancer Drugs Sales by Manufacturers
  • 3.1.1 Kidney Cancer Drugs Sales by Manufacturers (2015-2020)
  • 3.1.2 Kidney Cancer Drugs Sales Market Share by Manufacturers (2015-2020)
• 3.2 Kidney Cancer Drugs Revenue by Manufacturers
  • 3.2.1 Kidney Cancer Drugs Revenue by Manufacturers (2015-2020)
  • 3.2.2 Kidney Cancer Drugs Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Kidney Cancer Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Kidney Cancer Drugs Revenue in 2019
  • 3.2.5 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Kidney Cancer Drugs Price by Manufacturers
• 3.4 Kidney Cancer Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Kidney Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Kidney Cancer Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Kidney Cancer Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Kidney Cancer Drugs Market Size by Type (2015-2020)
  • 4.1.1 Global Kidney Cancer Drugs Sales by Type (2015-2020)
  • 4.1.2 Global Kidney Cancer Drugs Revenue by Type (2015-2020)
  • 4.1.3 Kidney Cancer Drugs Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Kidney Cancer Drugs Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Kidney Cancer Drugs Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Kidney Cancer Drugs Revenue Forecast by Type (2021-2026)
  • 4.2.3 Kidney Cancer Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Kidney Cancer Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Kidney Cancer Drugs Market Size by Application (2015-2020)
  • 5.1.1 Global Kidney Cancer Drugs Sales by Application (2015-2020)
  • 5.1.2 Global Kidney Cancer Drugs Revenue by Application (2015-2020)
  • 5.1.3 Kidney Cancer Drugs Price by Application (2015-2020)
• 5.2 Kidney Cancer Drugs Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Kidney Cancer Drugs Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Kidney Cancer Drugs Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Kidney Cancer Drugs Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Kidney Cancer Drugs by Country
  • 6.1.1 North America Kidney Cancer Drugs Sales by Country
  • 6.1.2 North America Kidney Cancer Drugs Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Kidney Cancer Drugs Market Facts & Figures by Type
• 6.3 North America Kidney Cancer Drugs Market Facts & Figures by Application

7 Europe

• 7.1 Europe Kidney Cancer Drugs by Country
  • 7.1.1 Europe Kidney Cancer Drugs Sales by Country
  • 7.1.2 Europe Kidney Cancer Drugs Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Kidney Cancer Drugs Market Facts & Figures by Type
• 7.3 Europe Kidney Cancer Drugs Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Kidney Cancer Drugs by Region
  • 8.1.1 Asia Pacific Kidney Cancer Drugs Sales by Region
  • 8.1.2 Asia Pacific Kidney Cancer Drugs Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Type
• 8.3 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Kidney Cancer Drugs by Country
  • 9.1.1 Latin America Kidney Cancer Drugs Sales by Country
  • 9.1.2 Latin America Kidney Cancer Drugs Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Kidney Cancer Drugs Market Facts & Figures by Type
• 9.3 Central & South America Kidney Cancer Drugs Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Kidney Cancer Drugs by Country
  • 10.1.1 Middle East and Africa Kidney Cancer Drugs Sales by Country
  • 10.1.2 Middle East and Africa Kidney Cancer Drugs Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Type
• 10.3 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Application

11 Company Profiles

• 11.1 Bayer
  • 11.1.1 Bayer Corporation Information
  • 11.1.2 Bayer Description and Business Overview
  • 11.1.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Bayer Kidney Cancer Drugs Products Offered
  • 11.1.5 Bayer Related Developments
• 11.2 Roche
  • 11.2.1 Roche Corporation Information
  • 11.2.2 Roche Description and Business Overview
  • 11.2.3 Roche Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Roche Kidney Cancer Drugs Products Offered
  • 11.2.5 Roche Related Developments
• 11.3 GlaxoSmithKline
  • 11.3.1 GlaxoSmithKline Corporation Information
  • 11.3.2 GlaxoSmithKline Description and Business Overview
  • 11.3.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 GlaxoSmithKline Kidney Cancer Drugs Products Offered
  • 11.3.5 GlaxoSmithKline Related Developments
• 11.4 Novartis
  • 11.4.1 Novartis Corporation Information
  • 11.4.2 Novartis Description and Business Overview
  • 11.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Novartis Kidney Cancer Drugs Products Offered
  • 11.4.5 Novartis Related Developments
• 11.5 Pfizer
  • 11.5.1 Pfizer Corporation Information
  • 11.5.2 Pfizer Description and Business Overview
  • 11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Pfizer Kidney Cancer Drugs Products Offered
  • 11.5.5 Pfizer Related Developments
• 11.6 Abbott Laboratories
  • 11.6.1 Abbott Laboratories Corporation Information
  • 11.6.2 Abbott Laboratories Description and Business Overview
  • 11.6.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Abbott Laboratories Kidney Cancer Drugs Products Offered
  • 11.6.5 Abbott Laboratories Related Developments
• 11.7 Active Biotech
  • 11.7.1 Active Biotech Corporation Information
  • 11.7.2 Active Biotech Description and Business Overview
  • 11.7.3 Active Biotech Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Active Biotech Kidney Cancer Drugs Products Offered
  • 11.7.5 Active Biotech Related Developments
• 11.8 Amgen
  • 11.8.1 Amgen Corporation Information
  • 11.8.2 Amgen Description and Business Overview
  • 11.8.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Amgen Kidney Cancer Drugs Products Offered
  • 11.8.5 Amgen Related Developments
• 11.9 Argos Therapeutics
  • 11.9.1 Argos Therapeutics Corporation Information
  • 11.9.2 Argos Therapeutics Description and Business Overview
  • 11.9.3 Argos Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Argos Therapeutics Kidney Cancer Drugs Products Offered
  • 11.9.5 Argos Therapeutics Related Developments
• 11.10 ArQule
  • 11.10.1 ArQule Corporation Information
  • 11.10.2 ArQule Description and Business Overview
  • 11.10.3 ArQule Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 ArQule Kidney Cancer Drugs Products Offered
  • 11.10.5 ArQule Related Developments
• 11.1 Bayer
  • 11.1.1 Bayer Corporation Information
  • 11.1.2 Bayer Description and Business Overview
  • 11.1.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Bayer Kidney Cancer Drugs Products Offered
  • 11.1.5 Bayer Related Developments
• 11.12 Bionomics
  • 11.12.1 Bionomics Corporation Information
  • 11.12.2 Bionomics Description and Business Overview
  • 11.12.3 Bionomics Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Bionomics Products Offered
  • 11.12.5 Bionomics Related Developments
• 11.13 Bristol-Myers Squibb
  • 11.13.1 Bristol-Myers Squibb Corporation Information
  • 11.13.2 Bristol-Myers Squibb Description and Business Overview
  • 11.13.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Bristol-Myers Squibb Products Offered
  • 11.13.5 Bristol-Myers Squibb Related Developments
• 11.14 Cerulean Pharma
  • 11.14.1 Cerulean Pharma Corporation Information
  • 11.14.2 Cerulean Pharma Description and Business Overview
  • 11.14.3 Cerulean Pharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Cerulean Pharma Products Offered
  • 11.14.5 Cerulean Pharma Related Developments
• 11.15 Exelixis
  • 11.15.1 Exelixis Corporation Information
  • 11.15.2 Exelixis Description and Business Overview
  • 11.15.3 Exelixis Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Exelixis Products Offered
  • 11.15.5 Exelixis Related Developments
• 11.16 Genentech
  • 11.16.1 Genentech Corporation Information
  • 11.16.2 Genentech Description and Business Overview
  • 11.16.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 Genentech Products Offered
  • 11.16.5 Genentech Related Developments
• 11.17 immatics biotechnologies
  • 11.17.1 immatics biotechnologies Corporation Information
  • 11.17.2 immatics biotechnologies Description and Business Overview
  • 11.17.3 immatics biotechnologies Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 immatics biotechnologies Products Offered
  • 11.17.5 immatics biotechnologies Related Developments
• 11.18 Immunicum
  • 11.18.1 Immunicum Corporation Information
  • 11.18.2 Immunicum Description and Business Overview
  • 11.18.3 Immunicum Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Immunicum Products Offered
  • 11.18.5 Immunicum Related Developments
• 11.19 Ono Pharmaceutical
  • 11.19.1 Ono Pharmaceutical Corporation Information
  • 11.19.2 Ono Pharmaceutical Description and Business Overview
  • 11.19.3 Ono Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 Ono Pharmaceutical Products Offered
  • 11.19.5 Ono Pharmaceutical Related Developments
• 11.20 Onyx Therapeutics
  • 11.20.1 Onyx Therapeutics Corporation Information
  • 11.20.2 Onyx Therapeutics Description and Business Overview
  • 11.20.3 Onyx Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 Onyx Therapeutics Products Offered
  • 11.20.5 Onyx Therapeutics Related Developments
• 11.21 Oxford BioMedica
  • 11.21.1 Oxford BioMedica Corporation Information
  • 11.21.2 Oxford BioMedica Description and Business Overview
  • 11.21.3 Oxford BioMedica Sales, Revenue and Gross Margin (2015-2020)
  • 11.21.4 Oxford BioMedica Products Offered
  • 11.21.5 Oxford BioMedica Related Developments
• 11.22 Prometheus Laboratories
  • 11.22.1 Prometheus Laboratories Corporation Information
  • 11.22.2 Prometheus Laboratories Description and Business Overview
  • 11.22.3 Prometheus Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.22.4 Prometheus Laboratories Products Offered
  • 11.22.5 Prometheus Laboratories Related Developments
• 11.23 Seattle Genetics
  • 11.23.1 Seattle Genetics Corporation Information
  • 11.23.2 Seattle Genetics Description and Business Overview
  • 11.23.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
  • 11.23.4 Seattle Genetics Products Offered
  • 11.23.5 Seattle Genetics Related Developments
• 11.24 Taiwan Liposome
  • 11.24.1 Taiwan Liposome Corporation Information
  • 11.24.2 Taiwan Liposome Description and Business Overview
  • 11.24.3 Taiwan Liposome Sales, Revenue and Gross Margin (2015-2020)
  • 11.24.4 Taiwan Liposome Products Offered
  • 11.24.5 Taiwan Liposome Related Developments
• 11.25 Tracon Pharmaceuticals
  • 11.25.1 Tracon Pharmaceuticals Corporation Information
  • 11.25.2 Tracon Pharmaceuticals Description and Business Overview
  • 11.25.3 Tracon Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.25.4 Tracon Pharmaceuticals Products Offered
  • 11.25.5 Tracon Pharmaceuticals Related Developments
• 11.26 Wilex
  • 11.26.1 Wilex Corporation Information
  • 11.26.2 Wilex Description and Business Overview
  • 11.26.3 Wilex Sales, Revenue and Gross Margin (2015-2020)
  • 11.26.4 Wilex Products Offered
  • 11.26.5 Wilex Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Kidney Cancer Drugs Market Estimates and Projections by Region
  • 12.1.1 Global Kidney Cancer Drugs Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Kidney Cancer Drugs Revenue Forecast by Regions 2021-2026
• 12.2 North America Kidney Cancer Drugs Market Size Forecast (2021-2026)
  • 12.2.1 North America: Kidney Cancer Drugs Sales Forecast (2021-2026)
  • 12.2.2 North America: Kidney Cancer Drugs Revenue Forecast (2021-2026)
  • 12.2.3 North America: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
• 12.3 Europe Kidney Cancer Drugs Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Kidney Cancer Drugs Sales Forecast (2021-2026)
  • 12.3.2 Europe: Kidney Cancer Drugs Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Kidney Cancer Drugs Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Kidney Cancer Drugs Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Kidney Cancer Drugs Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Kidney Cancer Drugs Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Kidney Cancer Drugs Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Kidney Cancer Drugs Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Kidney Cancer Drugs Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Kidney Cancer Drugs Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Kidney Cancer Drugs Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Kidney Cancer Drugs Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Kidney Cancer Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Kidney Cancer Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details